Salvage involved-field versus extended-field chemoradiotherapy for postoperative lymph node metastasis in esophageal squamous cell carcinoma: a retrospective clinical study
Authors:
Open Access
- 28 August 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-9
Abstract
Esophageal cancer is a major global health threat, causing over 187,000 deaths in China in 2022. Esophageal squamous cell carcinoma (ESCC) patients face high recurrence risks postradical esophagectomy, with 28.5% − 54% experiencing relapse. Current guidelines lack strong evidence for salvage treatments. Although salvage concurrent chemoradiotherapy has shown potential in improving outcomes, the optimal irradiation fields remain unclear. Therefore, this study aimed to compare salvage involved-field irradiation (IFI) versus extended-field irradiation (EFI) with concurrent chemoradiotherapy in postoperative thoracic ESCC patients with lymph node metastases, assessing whether IFI reduces toxicity without compromising efficacy. This retrospective study included 106 patients (2015–2024) treated with IFI (targeting involved nodes) or EFI (involved nodes + prophylactic areas) plus concurrent chemotherapy. Outcomes included local control rate (LCR), disease-free survival (DFS), overall survival (OS), disease control rate (DCR), objective response rate (ORR), adverse events (CTCAE v5.0), and elective nodal control (ENC, IFI group). With 57.2-month median follow-up, IFI and EFI showed comparable media OS (63.2 vs. 59.5 months, P = 0.519) and media DFS (28.4 vs. 17.8 months, P = 0.334). IFI achieved higher 3-/5-year LCR (81.1% vs. 61.8%; 60.8% vs. 49.4%, P = 0.026) and lower Grade 1–2 radiation esophagitis (29.3% vs. 46.9%), pneumonia (25.8% vs. 40.8%), and Grade 3–4 toxicity (32.8% vs. 57.1%, all P < 0.05). No significant differences in ORR/DCR were observed. IFI’s ENC was 10.5% (6/57). Salvage IFI demonstrates non-inferior efficacy to EFI with significantly reduced severe toxicity (32.8% vs. 57.1%, P = 0.011) and potential survival benefits in single-node metastases, supporting its clinical prioritization. This retrospective study was approved by the Ethics Committee of Jiangsu Cancer Hospital (Ethical Approval No. [KY-2024-020]).Keywords
This publication has 23 references indexed in Scilit:
- Tumor response and survival outcomes of salvage concurrent chemoradiotherapy with three-dimensional conformal radiotherapy and 5-fluorouracil/platinum-based chemotherapy for postoperative locoregional recurrence of esophageal squamous cell carcinomaEsophagus, 2022
- Risk prediction of occult lymph node metastasis in patients with clinical T1 through T2 N0 esophageal squamous cell carcinomaThe Journal of Thoracic and Cardiovascular Surgery, 2022
- Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell CarcinomaJAMA Surgery, 2021
- Involved-field chemoradiotherapy for postoperative solitary lymph node recurrence of esophageal cancerEsophagus, 2018
- Elective nodal irradiation is not necessary in chemoradiotherapy for postoperative loco-regional recurrent esophageal cancerJapanese Journal of Clinical Oncology, 2016
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trialThe Lancet Oncology, 2015
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- Three-Dimensional Conformal Radiation Therapy for Esophageal Squamous Cell Carcinoma: Is Elective Nodal Irradiation Necessary?International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent diseaseCancer, 2003
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999